Although much work remains, it is to be hoped that FLT3-mutated AML will soon join CML and APL as diseases that, while once near-uniform in their lethality, are now readily treatable via the use of precisely targeted therapies. This evidence concerns the gene FLT3 and acute promyelocytic leukemia.